HAE is a rare, debilitating, and life-threatening disease caused by an inherited deficiency or dysfunction of the C1 inhibitor. HAE is characterized by recurrent acute attacks of edema of the skin, face, and upper airway (including the larynx), and gastrointestinal and urogenital tracts. Symptoms typically increase in severity over a period of 24 hours and then subside over the next 24‒72 hours. Although the swelling is self-limiting, attacks are often associated with intense pain, disfigurement, disability, and/or vomiting. Laryngeal involvement may cause asphyxiation.

During this educational activity, we will review HAE, evaluate treatment options, and discuss resources available to patients and their families.

Learning Objectives
At the end of this educational activity, participants should be able to

1. Explain the clinical manifestations of HAE and its burden on patients’ lives
2. Discuss factors that contribute to HAE morbidity and mortality
3. Review the clinical evidence and roles for disease-targeted therapies in HAE management
4. Evaluate the benefits and risks of options available for HAE
5. Identify likely barriers to accessing new agents and offer potential solutions
6. Discuss educational resources and programs available to patients and their families

Method of Participation
There are no fees for participating in or receiving credit for this activity.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

Participants will receive a certificate upon successful completion of the activity, which includes the following:

• Completing the entire activity
• Completing the Pre- and Post-Activity Assessments, Activity Evaluation, and Application for Certificate of Credit forms

You must be logged in to your account to participate in this activity. Start by clicking “Begin” and viewing the “CE Info”; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save, or print your certificate of participation. The Area of Practice you indicated in your profile corresponds with your certificate type. A complete listing of all of your activities can be found in your profile.

Method for Calculating CE Credit
CE credit was calculated by the complexity of content.

Faculty Listing
Joshua S. Jacobs, MD
Medical Director, Allergy and Asthma Clinical Research Center
Walnut Creek, California

Faculty Disclosure
OptumHealth Education requires the disclosure of any relevant financial relationship a faculty member has with the manufacturer(s) of any product discussed in this educational presentation. The faculty reported the following:
Advisory Board: Shire, ViroPharma, Inc, Dyax Corp., and CSL Behring
Consultant: Shire, ViroPharma, Inc, and Dyax Corp.
Grant/Research Support: Shire, Dyax Corp., Merck, Forest  Laboratories, Inc., Boehringer Ingelheim, and CSL Behring
Speakers Bureau: Novartis, Shire, ViroPharma, Inc, Dyax Corp., Teva, and CSL Behring

Dr. Jacobs does not intend to discuss unapproved/investigative use of commercial products/devices.

Activity Planners
Sarah Chart-Hart, RN
Senior Director
OptumHealth Education

Arlene Rome, RN, BSN
Activity Manager
OptumHealth Education

Activity Planner Disclosures
OptumHealth Education requires the disclosure of any relevant financial relationship a planning member has with the manufacturer(s) of any product discussed in this educational presentation.

All of the planners reported that they are employees of and own stock in UnitedHealth Group.

OptumHealth Education ensures that the content is independent of commercial bias.

Reviewer Disclosures
To ensure fair balance and avoid bias, the content for this activity has been reviewed by an independent medical expert with no relevant financial relationships and has been approved by OptumHealth Education.

Provided By
This activity is provided by OptumHealth Education.

Commercial Support
This activity is supported by an independent educational grant from Dyax Corp.

Hardware/Software Requirements
To view this activity you will need Internet Explorer 7.0+ or Firefox 3.0+ with Windows Media Player 9+, RealPlayer 12+, or Adobe Flash Player 9+. Be sure to disable your pop-up blocking software prior to the beginning of this activity.